LINC01137 facilitates pancreatic cancer stemness via the miR-7155-5p/KLF12/AKT axis
Rattachement africain : cn. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Abstract Pancreatic cancer, of which pancreatic ductal adenocarcinoma (PDAC) is one of the most prevalent type, is one of the most malignant tumors, with a 5-year survival rate of about 10%. Pancreatic cancer stem cells play pivotal roles in chemoresistance and recurrence. Long non-coding RNAs (lncRNAs) have been identified as key regulators of the biological progression of various cancers. Recently, lncRNAs were found to be associated with cancer stem cells, which are related to chemoresistance. LINC01137 was predicted associated with pancreatic cancer stem cells, however, its function and underlying mechanisms in pancreatic cancer remain unclear. In this study, we found that LINC01137 was upregulated in pancreatic cancer tissues and cell lines. Its high expression correlated with advanced pathological stages and poor prognosis. Induction of LINC01137 expression boosted pancreatic cancer stemness, chemoresistance, and proliferation. Mechanistically, LINC01137 exerted its biological function by binding to miR-7155-5p to activate the KLF12/PI3K/AKT pathway. KLF12 also promoted LINC01137 expression. LINC01137 and KLF12 were involved in promoting PDAC tumorigenesis. Our results suggested that LINC01137 functions as an oncogene in pancreatic cancer and identified its post-transcriptional regulatory mechanisms, which may contribute to targeted therapy for pancreatic cancer.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- LINC01137 facilitates pancreatic cancer stemness via the miR-7155-5p/KLF12/AKT axis
- Date Crossref
- 14/02/2023
- Éditeur
- Springer Science and Business Media LLC
- Type
- posted-content
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Shanghai Jiao Tong University pays non établi dans la noticeUniversité ou école supérieure
-
Ruijin Hospital pays non établi dans la noticeÉtablissement de santé
-
State Key Laboratory of Oncogene and Related Genes pays non établi dans la noticeStructure de recherche
-
Renji Hospital pays non établi dans la noticeÉtablissement de santé
-
Shanghai Jiaotong University School of Medicine Department of General Surgery pays non établi dans la noticeUniversité ou école supérieure
-
State Key Laboratory of Oncogenes and Related Genes pays non établi dans la noticeStructure de recherche
Shanghai Jiao Tong University, Ruijin Hospital et State Key Laboratory of Oncogene and Related Genes, avec 3 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.